About Gunsutra
Gunsutra is a Healthcare company based in Delhi (India) founded in 2022. Point-of-care diagnostic devices and aptamer services in biotechnology. The company has 1 employees. Gunsutra offers products and services including Point-of-Care Diagnostic Devices and Custom Aptamer Generation. Its focus areas include Biotechnology, Research Services, Aptamer Development and Synthesis. Its legal entity in India is GUNSUTRA PVT. LTD (U33127DL2022PTC408336).
Company details
Gunsutra Pvt. Ltd. is recognized as a point-of-care diagnostic devices company, incubated at FITT, IIT Delhi. New-generation medical diagnostic devices in benchtop and handheld formats are developed, along with services for custom aptamer generation and synthesis. Proprietary SELEX technology is utilized to create aptamers for applications in therapeutics and diagnostics, serving academia and industries. Lead times of 3-6 months are maintained for processes, with Kd values evaluated through various techniques. Patents and publications support the technologys efficacy.
- Headquarters Delhi, India
- Employees 1
- SectorsHealthcare
- Email••••••••
- Legal Name Gunsutra Pvt. Ltd.
- Date of Incorporation 14 Dec, 2022
- Jurisdiction Hauzkhas, Delhi, India
- Employee Count1
Associated legal entities of Gunsutra
Gunsutra operates through Gunsutra Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Gunsutra Private Limited CIN U33127DL2022PTC408336 | Active | 14 Dec 2022 | New Delhi, Delhi | 2 | View details |
Products & Services of Gunsutra
Gunsutra offers a comprehensive portfolio of products and services, including Point-of-Care Diagnostic Devices and Custom Aptamer Generation.
New-generation diagnostic devices are developed in benchtop and handheld forms for medical applications.
Services for generating and synthesizing custom aptamers are provided for therapeutics, diagnostics, and assays using established processes.
Board of directors of Gunsutra Private Limited (Gunsutra)
Gunsutra Private Limited is the primary company behind Gunsutra. The board of Gunsutra Private Limited currently have 2 directors; the longest-serving is Pallavi Jha, appointed in 2022.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Pallavi Jha DIN 09824286 | Director | 14 Dec 2022 | 3 yrs 10 mo | Gunsutra Private Limited |
| Sandeep Kumar Jha DIN 09824287 | Director | 14 Dec 2022 | 3 yrs 10 mo | Gunsutra Private Limited |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Gunsutra
Gunsutra was founded in 2022.
Gunsutra is headquartered in Delhi, India. It is registered at Delhi, Delhi, India.
Gunsutra has 1 employees.
Gunsutra Pvt. Ltd. is recognized as a point-of-care diagnostic devices company, incubated at FITT, IIT Delhi. New-generation medical diagnostic devices in benchtop and handheld formats are developed, along with services for custom aptamer generation and synthesis. Proprietary SELEX technology is utilized to create aptamers for applications in therapeutics and diagnostics, serving academia and industries. Lead times of 3-6 months are maintained for processes, with Kd values evaluated through various techniques. Patents and publications support the technologys efficacy.
Gunsutra offers Point-of-Care Diagnostic Devices and Custom Aptamer Generation.
Gunsutra operates through Gunsutra Private Limited.
The legal entities of Gunsutra currently have 2 directors, including Pallavi Jha, Sandeep Kumar Jha.